During the second quarter, Emerald Health Therapeutics worked on improving the success of Pure Sunfarms, completing the licensing endeavors of its facilities, enabling the extraction of THC and CBD oil, and starting the distribution of new non-cannabis products that can inflect the endocannabinoid system to advance consumer's health.
(NASDAQ: CRBP) ('Corbus' or the 'Company'), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced its financial results for the second quarter ended June 30, 2019.
Such formulations take advantage of micro- PEA's synergistic or entourage effect on certain drugs impacting the endocannabinoid system. This means that lower doses of those drugs may be administered together with micro-PEA to achieve the desired therapeutic effect.
Makriyannis will champion the Company's pursuit of biosynthesizing cannabinoids identical to those found in nature, with the objective of standardizing pharmacological effects within the human endocannabinoid system. Highly specialized knowledge of cannabinoid biochemistry, as well as the macro human endocannabinoid system equips ICC and Biotii with a first mover competitive advantage to economically scale its synthesized cannabinoid platform.
The endocannabinoid system and other physiological systems can potentially mitigate the effects of organophosphate and carbamate toxicity when treated with medicaments affecting these systems in a time and dose-dependent format.
All human beings have an endocannabinoid system, which naturally produces cannabis-like compounds, the main ones being anandamide and 2-arachidonoylglycerol (2-AG) that bind to their receptors to produce beneficial effects.